» Articles » PMID: 30416002

Quantitative Assessment of Tumor Cell Proliferation in Brain Gliomas with Dynamic Contrast-Enhanced MRI

Overview
Journal Acad Radiol
Specialty Radiology
Date 2018 Nov 13
PMID 30416002
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale And Objectives: This study aimed to investigate whether volume transfer constant (K) and volume of extravascular extracellular space per unit volume of tissue (V) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) could quantitatively assess the tumor proliferation index (Ki-67) of gliomas noninvasively.

Materials And Methods: The preoperative DCE MRI data of 69 patients with pathologically confirmed glioma (28, 8, and 33 cases in grades Ⅱ, Ⅲ, and Ⅳ) were retrospectively reviewed. The maximal K and V were measured in the tumor body. The immunohistochemistry was used to detect the expression of Ki-67 proteins in glioma specimens. The Mann-Whitney U test was applied to analyze the differences in K, V, and Ki-67 index across histologically defined glioma grades. Spearman correlation was performed between K, V, and Ki-67 index. The receiver operating characteristic curve analysis was used to determine the cutoff values of K and V in distinguishing different Ki-67 index expression levels.

Results: K, V, and Ki-67 index of grade Ⅱ (0.027 min, 0.065, 4.04%) were significantly lower than those of grade Ⅲ (0.093 min, 0.297, 25.13%) and Ⅳ (0.100 min, 0.299, 25.37%). Both K and V significantly correlated with the Ki-67 index in all tumors and high-grade gliomas (HGGs, grade Ⅲ and Ⅳ). The receiver operating characteristic curve analysis revealed that the cutoff values for K (0.079 min) and V (0.249) provided the best combination of sensitivity and specificity to distinguish the gliomas with high Ki-67 index from those with low Ki-67 index.

Conclusion: The DCE MRI-derived parameters were valuable in assessing the tumor cell proliferation in HGG noninvasively.

Citing Articles

Distributed parameter model of dynamic contrast-enhanced MRI in the identification of IDH mutation, 1p19q codeletion, and tumor cell proliferation in glioma patients.

Zhao K, Huang H, Gao E, Qi J, Chen T, Zhao G Front Oncol. 2024; 14:1333798.

PMID: 39525622 PMC: 11544007. DOI: 10.3389/fonc.2024.1333798.


Dynamic glucose-enhanced MRI of gliomas: A preliminary clinical application.

Mo J, Xu X, Ma A, Lu M, Wang X, Rui Q NMR Biomed. 2024; 38(1):e5265.

PMID: 39500570 PMC: 11604297. DOI: 10.1002/nbm.5265.


Noninvasive assessment of Ki-67 labeling index in glioma patients based on multi-parameters derived from advanced MR imaging.

Hu Y, Zhang K Front Oncol. 2024; 14:1362990.

PMID: 38826787 PMC: 11140042. DOI: 10.3389/fonc.2024.1362990.


Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.

Li A, Iv M Front Radiol. 2023; 2:883293.

PMID: 37492665 PMC: 10365131. DOI: 10.3389/fradi.2022.883293.


Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.

Yang X, Hu C, Xing Z, Lin Y, Su Y, Wang X Eur Radiol. 2023; 33(10):7003-7014.

PMID: 37133522 DOI: 10.1007/s00330-023-09695-w.